US3896813A - Sutures having long-lasting biocidal properties - Google Patents
Sutures having long-lasting biocidal properties Download PDFInfo
- Publication number
- US3896813A US3896813A US243425A US24342572A US3896813A US 3896813 A US3896813 A US 3896813A US 243425 A US243425 A US 243425A US 24342572 A US24342572 A US 24342572A US 3896813 A US3896813 A US 3896813A
- Authority
- US
- United States
- Prior art keywords
- suture
- sutures
- antibiotic
- salt
- long
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 42
- 230000005923 long-lasting effect Effects 0.000 title claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 13
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 13
- 230000000844 anti-bacterial effect Effects 0.000 claims description 22
- 229930182566 Gentamicin Natural products 0.000 claims description 13
- 229960002518 gentamicin Drugs 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 229960001019 oxacillin Drugs 0.000 claims description 13
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 13
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 12
- 229930182555 Penicillin Natural products 0.000 claims description 11
- 108010093965 Polymyxin B Proteins 0.000 claims description 10
- 229920000024 polymyxin B Polymers 0.000 claims description 8
- 229960005266 polymyxin b Drugs 0.000 claims description 8
- 108010040201 Polymyxins Proteins 0.000 claims description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 5
- 229940049954 penicillin Drugs 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 abstract description 12
- 239000002253 acid Substances 0.000 abstract description 11
- 239000000243 solution Substances 0.000 abstract description 10
- 241000192125 Firmicutes Species 0.000 abstract description 4
- 238000005470 impregnation Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 150000002960 penicillins Chemical class 0.000 description 6
- 239000003139 biocide Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- VDUVBBMAXXHEQP-SLINCCQESA-M oxacillin sodium Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 VDUVBBMAXXHEQP-SLINCCQESA-M 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000003356 suture material Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- -1 cephalolexin Chemical class 0.000 description 4
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 229940083555 sodium cephalothin Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000002070 germicidal effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 2
- 229960000515 nafcillin Drugs 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229960003548 polymyxin b sulfate Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010021006 Tyrothricin Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229950004030 cefaloglycin Drugs 0.000 description 1
- FUBBGQLTSCSAON-PBFPGSCMSA-N cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- GSXRBRIWJGAPDU-BBVRJQLQSA-N tyrocidine A Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 GSXRBRIWJGAPDU-BBVRJQLQSA-N 0.000 description 1
- 229960003281 tyrothricin Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/26—Textiles, e.g. towels, beds, cloths
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Definitions
- ABSTRACT Sutures are provided with long-lasting biocidal properties against both gram-negative and gram-positive bacteria by incorporating substantially water-insoluble salts of an acid antibiotic and a basic antibiotic into the body of the suture.
- the sutures can be prepared by sequentially impregnating the sutures with aqueous solutions of the respective antibiotics or by first forming the water-soluble salt of the antibiotic and impregnating the suture with an organic solution of the water-insoluble salt.
- the present invention relates to sutures having longlasting anti-bacterial properties and to methods of providing such sutures.
- antibiotics have been previously employed to coat or impregnate various textile materials in order to induce therein bactericidal properties.
- U.S. Pat. No. 2,830,011 to Parker et al except for neomycin such materials have been limited to singleuse purposes and have been discarded or thrown away following such single use. The reason for this was the fact that the antibiotics were not sufficiently stable or substantive and consequently could not remain in active acti-bacterial form therein following cleaning operations prior to reuse. Consequently, use of antibiotics as impregnants has been limited and their commercial acceptance has not been as widespread as their characteristics indicate.
- biocides should be tenaciously held by the suture to prevent repid leaching and yet the biocide cannot be so intimately held that its anti-bacterial activity is lost.
- the problem in the art has been to provide feasible techniques to make sutures with long-lasting anti-bacterial properties.
- Sutures having long-lasting biocidal properties are provided according to the invention by providing uniformily throughout the body of the suture a substantially water-insoluble salt of an acid antibiotic and basic antibiotic.
- the bactericide is actually incorporated within the body of the suture and is not merely deposited on the surface thereof.
- the insoluble anti-bacterial salts of the invention comprise a cation of a basic antibiotic and an anion of an acid antibiotic and have been found surprisingly to provide long-lasting effectiveness against both gram-positive and gram-negative bacteria despite their high water-insolubility.
- the solubility in water at C of the antibiotic salts of the invention does not exceed about 4.0 mg. per ml. and preferably does not exceed 2.0 mg. per ml.
- the particularly preferred antibiotic salts of the invention have a solubility of less than 1.0 mg. per ml. yet exhibit extraordinary effectiveness against both gram-positive and gram-negative bacteria.
- biocidal materials are substantially insoluble in water, they are generally soluble in organic solvents (e.g. methyl and ethyl alcohol, ether, ethyl acetate, benzene, chloroform, acetone, dimethylsulfoxide and other common organic solvents) and can generally be dissolved in aqueous organic solvents.
- a persistent reservoir of a water-insoluble agent is established within the suture which offers broad spectrum antibiotic activity.
- Suitable basic antibiotics which may be used to form the substantially water-insoluble salts of the invention include those classified as polypeptides, sugars and bases.
- polypeptides may be mentioned bacitracin, polymyxins, tyrothricin and vancomycin.
- Sugars include neomycin, erythromycin, streptomycin, vancomycin and nystatin.
- Bases include cycloserine, tetracycline, aureomycin and terramycin.
- the preferred basic antibiotics are gentamicin and polymixin B.
- Suitable acid antibiotics are penicillins, fumagillin and cephalosporins such as cephalolexin, cephaloglycin, cephaloridine and cephalothin.
- penicillins as used herein means acid antibiotics which are structurally o-substituted penicillanic acids such as Penicillins G, N, O and V, nafcillin, methicillin. oxacillin and the like.
- Both the cation of the basic antibiotic and the anion of the acid antibiotic are conveniently provided in aqueous solutions of the respective antibiotics or their water-soluble addition salts.
- Mineral acid salts of the basic antibiotic are particularly good sources for the cations whereas the alkali metal, e.g. Na and K salts of the acid antibiotic are preferred sources for the anions.
- Preparation of the substantially water-insoluble salt is simply accomplished by combining these aqueous solutions of the cations and anions to form the salt which will precipitate.
- the long'lasting anti-bacterial materials mentioned above can, according to the invention, be provided in situ in any suture material which is swellable but not itself particularly soluble in the solution employed for the impregnation.
- the substrate is simply contacted with a solution of the water-insoluble anti-bacterial salt in a solvent such as an organic solvent or which is also a swelling agent for the suture.
- a solvent such as an organic solvent or which is also a swelling agent for the suture.
- the sol vent swells the suture and the solvent plus salt will penetrate into the body of the suture material.
- the solvent can then be removed by evaporation, extraction, etc., and the salt will remain incorporated into the body of the suture.
- This impregnation procedure offers a convenient method of introducing a water-insoluble bactericide into the body of the suture that remains surprisingly effective against both gram-positive and gramnegative bacteria.
- this method offers the additional advantages of enabling precise determination of the concentrations of each antibiotic present in the suture.
- An alternative method of introducing the insoluble germicide into the suture comprises depositing the salt in situ by sequentially treating the suture with a solution of the acid antibiotic and a solution of the basic antibiotic solution or vice versa.
- This method has been surprisingly found to incorporate higher concentrations of the second added antibiotic in a single impregnation than can be obtained by an impregnation with the same antibiotic alone, that is, without the previously added antibiotic.
- the solutions will include a swelling agent which enhances impregnation into the suture.
- the swelling agent may be water or an organic solvent.
- the solutions can be heated to aid impregnation provided that the biocides are not destroyed by such heat.
- EXAMPLE I immersed in a 10 percent aqueous solution of gentamicin sulfate maintained at approximately F for about 8 to 24 hours. After this treatment the suture is removed from the oven and blotted to remove excess water. The suture is then vacuum dried at lF for 16 to 24 hours and its dry weight taken to determine the mg/yd pickup.
- the resulting suture is then subjected to a second treatment comprising immersing the suture in a percent aqueous solution of sodium oxacillin maintained at 100F for a period of 2-4 hours.
- a second treatment comprising immersing the suture in a percent aqueous solution of sodium oxacillin maintained at 100F for a period of 2-4 hours.
- the drying process described above is repeated and the mg/yd pickup is calculated.
- the aqueous solution employed in the above treatments are each capable of swelling the silk suture and an intra-fibrillar precipitate of gentamicin oxacillinate is thus formed well within the body of the suture.
- the precipitate is then held tenaciously within the body of the suture such that it is very resistant to the leaching action of body fluids and this provides a persistant reservoir for both the gentamicin and the oxacillin antibiotics. It is also resistant to repeated washings and thus provides sutures which are persistently effective against gram negative and gram positive bacteria even after re peated washings.
- Example I The procedure of Example I is repeated substituting polymyxin B sulfate for gentamicin sulfate to provide a silk suture having incorporated therein polymyxin B oxacillinate. The results of the treatments are summarized in the following Table 2.
- Example III The procedure of Example I is repeated substituting sodium cephalothin for sodium oxacillin to provide a suture having incorporated therein polymyxin B cephalothinate. The results of the impregnations are summarized below in Table 3:
- Substantially water-insoluble polymyxin B oxacillinate is first prepared by mixing together at room temperature a 10 percent aqueous solution of polymyxin B sulfate and a 10 percent aqueous solution of sodium oxacillin. The resulting precipitate of polymyxin B oxacillinate is recovered and dissolved in /25 ethyl alcohol/water.
- Gentamicin oxacillinate is prepared as described in Example III by substituting gentamicin sulfate for polym xin B sulfate.
- a size 2/0 braided Dacron polyester (polyethylene terephthalate) surgical suture having incorporated therein gentamicin oxacillinate is prepared by following the impregnation procedure described in Example IV.
- the suture material can be natural, such as silk, gut and cotton, or synthetic such as regenerated cellulose, cellulose esters, polyamides, polyacrylics, polyesters, polyvinyls and polyolefins.
- anti-bacterial salts of the invention have virtually unmeasurable solubility in water.
- sutures provided with these salts exhibit longlasting anti-bacterial activity. Therefore, it is considered appropriate to include within the meaning of substantially insoluble, those materials which have a solubility in water which ranges from substantially undetectable to about 4.0 mg per ml at 25C.
- the amount of insoluble compound provided in the suture can vary widely and large amounts can be provided by repeating the impregnation process. Antibacterial activity is achieved with very small amounts of material. In general, the amount of antibacterial material in the suture will depend upon the intended use, and in general, up to 25 or even 50 percent by weight based on the suture material is contemplated. The minimum amount of biocide is largely a matter of choice, but trace amounts and amounts as low as l.() percent or 0.1 percent by weight, based on the weight of the suture, are effective.
- anti-bacterial material can be provided in some cases, it is generally not practical to do so since lesser amounts achieve the desired persistent anti-bacterial action and the preferred amount of anti-bacterial material for sutures is therefore between 0.1 and percent by weight based on the weight of the suture material.
- sutures provided with insoluble biodical salts according to the invention is demonstrated by placing sutures prepared according to the invention as shown in the foregoing examples, in contact with organism such as Bacillus subtilis, Escherichia coli or Staphlococcus aureus. Even after repeated washings, the area around a silk suture containing the bactericides of the invention will remain clear of the organism whereas no inhibition thereof is noted when placing a similarly washed thread originally treated with an individual antibiotic in the same environment. Similarly, the persistent antibacterial nature of the suture is illustrated by in vivo testings in mice. Silk sutures treated according to the invention, after being implanted in mice for five days, show no growth of organisms when removed and placed in a culture medium.
- the sutures to which the invention relates are, with the exception of the long-lasting biocides incorporated therein, of conventional configuration and materials.
- the sutures are generally sterilized and may be attached to suture needles in the usual manner and packaged in a sterile condition.
- insoluble salts formed from gentamicin and penicillins particularly the synthetic penicillins effective against gram-positive bacteria such as nafcillin, methicillin and oxacillin.
- the gentamicin cation is effective against pseudomonads and proteus and the synthetic penicillins are effective against penicillin resistant strains of staphglcocci.
- the antimicrobial results are excellent and there is substantially no tissue reaction.
- a surgical suture having long-lasting bactericidal properties comprising a suture strand having incorporated substantially uniformly within the body thereof throughout its length an effective amount of a substantially water-insoluble salt of a penicillin and a basic antibiotic selected from the group consisting of gentamicin and a polymyxin, said substantially water-insoluble salt being held tenaciously in said suture strand to provide a long-lasting source of both said antibiotics.
- substantially water-insoluble salt is a'salt of gentamicin and oxacillin.
- substantially water-insoluble salt is a salt of polymyxin and oxacillin.
- suture is of a material selected from silk and gut.
Abstract
Sutures are provided with long-lasting biocidal properties against both gram-negative and gram-positive bacteria by incorporating substantially water-insoluble salts of an acid antibiotic and a basic antibiotic into the body of the suture. The sutures can be prepared by sequentially impregnating the sutures with aqueous solutions of the respective antibiotics or by first forming the water-soluble salt of the antibiotic and impregnating the suture with an organic solution of the waterinsoluble salt.
Description
United States Patent [191 Kurtz 1 1 *July 29, 1975 1 SUTURES HAVING LONG-LASTING BIOCIDAL PROPERTIES [75] Inventor: Leonard D. Kurtz, Woodmere, N.Y.
[73] Assignee: Sutures, Inc., Coventry, Conn.
[ Notice: The portion of the term of this patent subsequent to Feb. 15, 1989, has been disclaimed.
[22] Filed: Apr. 12, 1972 211 Appl. No.: 243,425
Related U.S. Application Data [63] Continuation-in-part of Ser. No. 851,739, Aug. 20, 1969, abandoned, which is a continuation-in-part of Ser. No. 648,247, June 23, 1967, abandoned.
3,069,320 12/1962 Vitalis 424/181 3,235,556 12/1966 Wakeman et al..... 260/286 3,328,409 6/1967 Wakeman et a1. 260/286 3,388,704 6/1968 Kurtz 128/3355 FOREIGN PATENTS OR APPLICATIONS 788,968 1/1958 United Kingdom 424/329 OTHER PUBLICATIONS The Merck Index, Eighth Edition; Merck & Co., Inc., Rahway, NJ. USA, pgs. 485, 771, 790 & 848.
Primary Examiner-Frederick E. Waddell Attorney, Agent, or FirmLarson, Taylor and Hinds [57] ABSTRACT Sutures are provided with long-lasting biocidal properties against both gram-negative and gram-positive bacteria by incorporating substantially water-insoluble salts of an acid antibiotic and a basic antibiotic into the body of the suture. The sutures can be prepared by sequentially impregnating the sutures with aqueous solutions of the respective antibiotics or by first forming the water-soluble salt of the antibiotic and impregnating the suture with an organic solution of the water-insoluble salt.
8 Claims, N0 Drawings SUTURES HAVING LONG-LASTING BIOCIDAL PROPERTIES This is a continuation in part of my US. application Ser. No. 851,739 filed Aug. 20, 1969, now abandoned, which in turn is a continuation in part of application Ser. No. 648,247, filed June 23, 1967, now abandoned.
The present invention relates to sutures having longlasting anti-bacterial properties and to methods of providing such sutures.
There have been several attempts to provide antibacterial material in sutures. For example, US. Pat. Nos. 86 l ,23 l and 2,751,910 relate to providing germicidal sutures.
Also, antibiotics have been previously employed to coat or impregnate various textile materials in order to induce therein bactericidal properties. As noted in U.S. Pat. No. 2,830,011 to Parker et al, however, except for neomycin such materials have been limited to singleuse purposes and have been discarded or thrown away following such single use. The reason for this was the fact that the antibiotics were not sufficiently stable or substantive and consequently could not remain in active acti-bacterial form therein following cleaning operations prior to reuse. Consequently, use of antibiotics as impregnants has been limited and their commercial acceptance has not been as widespread as their characteristics indicate.
it is thus desirable that the biocides should be tenaciously held by the suture to prevent repid leaching and yet the biocide cannot be so intimately held that its anti-bacterial activity is lost. The problem in the art has been to provide feasible techniques to make sutures with long-lasting anti-bacterial properties.
Sutures having long-lasting biocidal properties are provided according to the invention by providing uniformily throughout the body of the suture a substantially water-insoluble salt of an acid antibiotic and basic antibiotic. The bactericide is actually incorporated within the body of the suture and is not merely deposited on the surface thereof. The insoluble anti-bacterial salts of the invention comprise a cation of a basic antibiotic and an anion of an acid antibiotic and have been found surprisingly to provide long-lasting effectiveness against both gram-positive and gram-negative bacteria despite their high water-insolubility. In general, the solubility in water at C of the antibiotic salts of the invention does not exceed about 4.0 mg. per ml. and preferably does not exceed 2.0 mg. per ml. in fact, the particularly preferred antibiotic salts of the invention have a solubility of less than 1.0 mg. per ml. yet exhibit extraordinary effectiveness against both gram-positive and gram-negative bacteria. While the biocidal materials are substantially insoluble in water, they are generally soluble in organic solvents (e.g. methyl and ethyl alcohol, ether, ethyl acetate, benzene, chloroform, acetone, dimethylsulfoxide and other common organic solvents) and can generally be dissolved in aqueous organic solvents.
Thus, in accordance with the present invention a persistent reservoir of a water-insoluble agent is established within the suture which offers broad spectrum antibiotic activity.
Suitable basic antibiotics which may be used to form the substantially water-insoluble salts of the invention include those classified as polypeptides, sugars and bases. Among the polypeptides may be mentioned bacitracin, polymyxins, tyrothricin and vancomycin. Sugars include neomycin, erythromycin, streptomycin, vancomycin and nystatin. Bases include cycloserine, tetracycline, aureomycin and terramycin. The preferred basic antibiotics are gentamicin and polymixin B.
Illustrative of suitable acid antibiotics are penicillins, fumagillin and cephalosporins such as cephalolexin, cephaloglycin, cephaloridine and cephalothin. The term penicillins as used herein means acid antibiotics which are structurally o-substituted penicillanic acids such as Penicillins G, N, O and V, nafcillin, methicillin. oxacillin and the like.
Both the cation of the basic antibiotic and the anion of the acid antibiotic are conveniently provided in aqueous solutions of the respective antibiotics or their water-soluble addition salts. Mineral acid salts of the basic antibiotic are particularly good sources for the cations whereas the alkali metal, e.g. Na and K salts of the acid antibiotic are preferred sources for the anions. Preparation of the substantially water-insoluble salt is simply accomplished by combining these aqueous solutions of the cations and anions to form the salt which will precipitate.
The long'lasting anti-bacterial materials mentioned above can, according to the invention, be provided in situ in any suture material which is swellable but not itself particularly soluble in the solution employed for the impregnation. The substrate is simply contacted with a solution of the water-insoluble anti-bacterial salt in a solvent such as an organic solvent or which is also a swelling agent for the suture. In this manner the sol vent swells the suture and the solvent plus salt will penetrate into the body of the suture material. The solvent can then be removed by evaporation, extraction, etc., and the salt will remain incorporated into the body of the suture. This impregnation procedure offers a convenient method of introducing a water-insoluble bactericide into the body of the suture that remains surprisingly effective against both gram-positive and gramnegative bacteria. In addition, this method offers the additional advantages of enabling precise determination of the concentrations of each antibiotic present in the suture. An alternative method of introducing the insoluble germicide into the suture comprises depositing the salt in situ by sequentially treating the suture with a solution of the acid antibiotic and a solution of the basic antibiotic solution or vice versa. This method has been surprisingly found to incorporate higher concentrations of the second added antibiotic in a single impregnation than can be obtained by an impregnation with the same antibiotic alone, that is, without the previously added antibiotic. In either case, the solutions will include a swelling agent which enhances impregnation into the suture. The swelling agent may be water or an organic solvent. The solutions can be heated to aid impregnation provided that the biocides are not destroyed by such heat.
The invention is further illustrated in the examples which follow. 7
EXAMPLE I immersed in a 10 percent aqueous solution of gentamicin sulfate maintained at approximately F for about 8 to 24 hours. After this treatment the suture is removed from the oven and blotted to remove excess water. The suture is then vacuum dried at lF for 16 to 24 hours and its dry weight taken to determine the mg/yd pickup.
The resulting suture is then subjected to a second treatment comprising immersing the suture in a percent aqueous solution of sodium oxacillin maintained at 100F for a period of 2-4 hours. The drying process described above is repeated and the mg/yd pickup is calculated.
The results of the above described treatments are set forth in the following Table I.
The aqueous solution employed in the above treatments are each capable of swelling the silk suture and an intra-fibrillar precipitate of gentamicin oxacillinate is thus formed well within the body of the suture. The precipitate is then held tenaciously within the body of the suture such that it is very resistant to the leaching action of body fluids and this provides a persistant reservoir for both the gentamicin and the oxacillin antibiotics. It is also resistant to repeated washings and thus provides sutures which are persistently effective against gram negative and gram positive bacteria even after re peated washings.
For comparison, a similar suture is subjected to impregnation with a 10 percent aqueous solution of sodium oxacillin alone. The pick up of oxacillin in the suture is found to be 0.4 mg/yd. Comparing the oxacillin pickup in this suture with that of the method of the present invention shows that the method of the present invention is capable of introducing larger amounts of the second added antibiotic in a single impregnation.
EXAMPLE I] The procedure of Example I is repeated substituting polymyxin B sulfate for gentamicin sulfate to provide a silk suture having incorporated therein polymyxin B oxacillinate. The results of the treatments are summarized in the following Table 2.
Total mg/yd. pickup Comparing the pickup of oxacillin in this example with the pickup of oxacillin by impregnations with a 10 percent aqueous solution of sodium oxacillin shown in Example I demonstrates that sutures having greater amounts of the second added antibiotic can be provided.
EXAMPLE III The procedure of Example I is repeated substituting sodium cephalothin for sodium oxacillin to provide a suture having incorporated therein polymyxin B cephalothinate. The results of the impregnations are summarized below in Table 3:
For comparison, a similar suture is subjected to impregnation with a 10 percent aqueous solution of sodium cephalothin along. The highest level of sodium cephalothin that is incorporated in the suture is 1.0 mg/yd.
EXAMPLE IV Substantially water-insoluble polymyxin B oxacillinate is first prepared by mixing together at room temperature a 10 percent aqueous solution of polymyxin B sulfate and a 10 percent aqueous solution of sodium oxacillin. The resulting precipitate of polymyxin B oxacillinate is recovered and dissolved in /25 ethyl alcohol/water.
20 yards of surgical silk suture size 2/0 is predried in a vacuum oven at F for 3 hours. The dry weight of the suture is determined and it is placed in the saturated solution of polymyxin B oxacillinate for 2 hours. A platform is used to cover precipitate in the treating container in order to avoid surface crust on the suture. The suture is then removed from the solution, the excess solution blotted off and the suture vacuum dried for 16 hours at 100F. The pickup of polymyxin B oxacillinate is found to be 1.2 mg/yd.
EXAMPLE V Gentamicin oxacillinate is prepared as described in Example III by substituting gentamicin sulfate for polym xin B sulfate. A size 2/0 braided Dacron polyester (polyethylene terephthalate) surgical suture having incorporated therein gentamicin oxacillinate is prepared by following the impregnation procedure described in Example IV.
The suture material can be natural, such as silk, gut and cotton, or synthetic such as regenerated cellulose, cellulose esters, polyamides, polyacrylics, polyesters, polyvinyls and polyolefins.
Several of the anti-bacterial salts of the invention have virtually unmeasurable solubility in water. However, sutures provided with these salts exhibit longlasting anti-bacterial activity. Therefore, it is considered appropriate to include within the meaning of substantially insoluble, those materials which have a solubility in water which ranges from substantially undetectable to about 4.0 mg per ml at 25C.
The amount of insoluble compound provided in the suture can vary widely and large amounts can be provided by repeating the impregnation process. Antibacterial activity is achieved with very small amounts of material. In general, the amount of antibacterial material in the suture will depend upon the intended use, and in general, up to 25 or even 50 percent by weight based on the suture material is contemplated. The minimum amount of biocide is largely a matter of choice, but trace amounts and amounts as low as l.() percent or 0.1 percent by weight, based on the weight of the suture, are effective. Although more anti-bacterial material can be provided in some cases, it is generally not practical to do so since lesser amounts achieve the desired persistent anti-bacterial action and the preferred amount of anti-bacterial material for sutures is therefore between 0.1 and percent by weight based on the weight of the suture material.
The persistent anti-bacterial activity of sutures provided with insoluble biodical salts according to the invention is demonstrated by placing sutures prepared according to the invention as shown in the foregoing examples, in contact with organism such as Bacillus subtilis, Escherichia coli or Staphlococcus aureus. Even after repeated washings, the area around a silk suture containing the bactericides of the invention will remain clear of the organism whereas no inhibition thereof is noted when placing a similarly washed thread originally treated with an individual antibiotic in the same environment. Similarly, the persistent antibacterial nature of the suture is illustrated by in vivo testings in mice. Silk sutures treated according to the invention, after being implanted in mice for five days, show no growth of organisms when removed and placed in a culture medium.
The sutures to which the invention relates are, with the exception of the long-lasting biocides incorporated therein, of conventional configuration and materials. The sutures are generally sterilized and may be attached to suture needles in the usual manner and packaged in a sterile condition.
Particularly good results have been achieved with insoluble salts formed from gentamicin and penicillins, particularly the synthetic penicillins effective against gram-positive bacteria such as nafcillin, methicillin and oxacillin. The gentamicin cation is effective against pseudomonads and proteus and the synthetic penicillins are effective against penicillin resistant strains of staphglcocci. When provided in a suture according to the present invention, the antimicrobial results are excellent and there is substantially no tissue reaction.
It is claimed:
1. A surgical suture having long-lasting bactericidal properties comprising a suture strand having incorporated substantially uniformly within the body thereof throughout its length an effective amount of a substantially water-insoluble salt of a penicillin and a basic antibiotic selected from the group consisting of gentamicin and a polymyxin, said substantially water-insoluble salt being held tenaciously in said suture strand to provide a long-lasting source of both said antibiotics.
2. The surgical suture of claim 1 wherein the basic antibiotic is gentamicin.
3. The surgical suture of claim 1 wherein the basic antibiotic is a polymyxin.
4. The surgical suture of claim 1 wherein the basic antibiotic is polymyxin B.
5. The surgical suture of claim 4 wherein the penicillin is oxacillin.
6. The surgical suture of claim 1 wherein the substantially water-insoluble salt is a'salt of gentamicin and oxacillin.
7. The surgical suture of claim 1 wherein the substantially water-insoluble salt is a salt of polymyxin and oxacillin.
8. The surgical suture of claim 1 wherein the suture is of a material selected from silk and gut.
Claims (8)
1. A SURGICAL SUTURE HAVING LONG-LASTING BACTERICIDAL PROPERTIES COMPRISING A SUTURE STRAND HAVING INCORPORATED SUBSTANTIALLY UNIFORMLY WITHIN THE BODY THEREOF THROUGHOUT ITS LENGTH AN EFFECTIVE AMOUNT OF A SUBSTANTIALLY WATER-INSOLUBLE SALT OF A PENICILLIN AND A BASIC ANTIBIOTIC SELECTED FROM THE GROUP CONSISTING OF GENTAMICIN AND A POLYMYXIN, SAID SUBSTANTIALLY WATER-INSOLUBLE SALT BEING HELD TENACIOUSLY IN SAID SUTURE STRAND TO PROVIDE A LONG-LASTING SOURCE OF BOTH SAID ANTIBIOTICS.
2. The surgical suture of claim 1 wherein the basic antibiotic is gentamicin.
3. The surgical suture of claim 1 wherein the basic antibiotic is a polymyxin.
4. The surgical suture of claim 1 wherein the basic antibiotic is polymyxin B.
5. The surgical suture of claim 4 wherein the penicillin is oxacillin.
6. The surgical suture of claim 1 wherein the substantially water-insoluble salt is a salt of gentamicin and oxacillin.
7. The surgical suture of claim 1 wherein the substantially water-insoluble salt is a salt of polymyxin and oxacillin.
8. The surgical suture of claim 1 wherein the suture is of a material selected from silk and gut.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US243425A US3896813A (en) | 1967-06-23 | 1972-04-12 | Sutures having long-lasting biocidal properties |
ZA724131A ZA724131B (en) | 1972-04-12 | 1972-06-15 | Sutures having long-lasting biocidal properties |
GB2934072A GB1401842A (en) | 1972-04-12 | 1972-06-22 | Sutures having long-lasting ciocidal properties |
IT12754/72A IT968120B (en) | 1972-04-12 | 1972-06-28 | THREADS FOR SUTURES WITH LONG-LASTING BIOCIDAL PROPERTIES |
DE2232731A DE2232731A1 (en) | 1972-04-12 | 1972-07-04 | SURGICAL SUTURE MATERIAL WITH LONG-LASTING Germicidal Properties |
FR7229855A FR2179691B1 (en) | 1972-04-12 | 1972-08-21 | |
JP47090525A JPS4914800A (en) | 1972-04-12 | 1972-09-11 | |
DE2320468A DE2320468A1 (en) | 1972-04-12 | 1973-04-21 | SURGICAL SUTURE |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64824767A | 1967-06-23 | 1967-06-23 | |
US85173969A | 1969-08-20 | 1969-08-20 | |
US243425A US3896813A (en) | 1967-06-23 | 1972-04-12 | Sutures having long-lasting biocidal properties |
Publications (1)
Publication Number | Publication Date |
---|---|
US3896813A true US3896813A (en) | 1975-07-29 |
Family
ID=27399662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US243425A Expired - Lifetime US3896813A (en) | 1967-06-23 | 1972-04-12 | Sutures having long-lasting biocidal properties |
Country Status (1)
Country | Link |
---|---|
US (1) | US3896813A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024871A (en) * | 1975-07-23 | 1977-05-24 | Ethicon, Inc. | Antimicrobial sutures |
US4542169A (en) * | 1983-12-12 | 1985-09-17 | Rohm And Haas Company | Biomedical devices containing isothiazolones to control bacteria growth |
US4708870A (en) * | 1985-06-03 | 1987-11-24 | E. I. Du Pont De Nemours And Company | Method for imparting antimicrobial activity from acrylics |
WO1988000062A1 (en) * | 1986-07-04 | 1988-01-14 | Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny I | Ligature material |
US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
WO1989009627A1 (en) * | 1988-04-07 | 1989-10-19 | Edward Shanbrom | Non-thrombogenic intravascular catheter coated with polymyxin |
US4895566A (en) * | 1986-07-25 | 1990-01-23 | C. R. Bard, Inc. | Coating medical devices with cationic antibiotics |
US5009229A (en) * | 1989-12-06 | 1991-04-23 | Medtronic, Inc. | Steroid eluting intramuscular lead |
US5086787A (en) * | 1989-12-06 | 1992-02-11 | Medtronic, Inc. | Steroid eluting intramuscular lead |
EP0607284A1 (en) * | 1991-10-10 | 1994-07-27 | Menlo Care Inc. | Therapeutic agent in hydrophilic matrix |
US5584877A (en) * | 1993-06-25 | 1996-12-17 | Sumitomo Electric Industries, Ltd. | Antibacterial vascular prosthesis and surgical suture |
US6416549B1 (en) | 1999-07-19 | 2002-07-09 | Sulzer Carbomedics Inc. | Antithrombogenic annuloplasty ring having a biodegradable insert |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US861231A (en) * | 1906-05-03 | 1907-07-23 | Johnson & Johnson | Surgical ligature. |
US2743268A (en) * | 1952-07-12 | 1956-04-24 | Lilly Co Eli | Erythromycin-penicillin |
US2751910A (en) * | 1953-06-25 | 1956-06-26 | Edward L Howes | Sutures |
US2830011A (en) * | 1957-02-07 | 1958-04-08 | American Cyanamid Co | Textile fabrics containing neomycin |
US3069320A (en) * | 1958-11-18 | 1962-12-18 | American Cyanamid Co | Synergistic sanitizing process with neomycin and selected cationic surface active quaternary ammonium salts |
US3235556A (en) * | 1963-03-05 | 1966-02-15 | Millmaster Onyx Corp | Alkyl isoquinolinium salts of aromatic carboxylic acids |
US3328409A (en) * | 1964-02-10 | 1967-06-27 | Millmaster Onyx Corp | Quaternary salts of dimer acids |
US3388704A (en) * | 1964-10-02 | 1968-06-18 | Sutures Inc | Microbiocidal sutures containing quaternary ammonium compounds and method for making |
-
1972
- 1972-04-12 US US243425A patent/US3896813A/en not_active Expired - Lifetime
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US861231A (en) * | 1906-05-03 | 1907-07-23 | Johnson & Johnson | Surgical ligature. |
US2743268A (en) * | 1952-07-12 | 1956-04-24 | Lilly Co Eli | Erythromycin-penicillin |
US2751910A (en) * | 1953-06-25 | 1956-06-26 | Edward L Howes | Sutures |
US2830011A (en) * | 1957-02-07 | 1958-04-08 | American Cyanamid Co | Textile fabrics containing neomycin |
US3069320A (en) * | 1958-11-18 | 1962-12-18 | American Cyanamid Co | Synergistic sanitizing process with neomycin and selected cationic surface active quaternary ammonium salts |
US3235556A (en) * | 1963-03-05 | 1966-02-15 | Millmaster Onyx Corp | Alkyl isoquinolinium salts of aromatic carboxylic acids |
US3328409A (en) * | 1964-02-10 | 1967-06-27 | Millmaster Onyx Corp | Quaternary salts of dimer acids |
US3388704A (en) * | 1964-10-02 | 1968-06-18 | Sutures Inc | Microbiocidal sutures containing quaternary ammonium compounds and method for making |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024871A (en) * | 1975-07-23 | 1977-05-24 | Ethicon, Inc. | Antimicrobial sutures |
US5021241A (en) * | 1983-10-14 | 1991-06-04 | Sumitomo Pharmaceuticals Company, Limited | Long-term sustained-release preparation |
US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
US4542169A (en) * | 1983-12-12 | 1985-09-17 | Rohm And Haas Company | Biomedical devices containing isothiazolones to control bacteria growth |
US4708870A (en) * | 1985-06-03 | 1987-11-24 | E. I. Du Pont De Nemours And Company | Method for imparting antimicrobial activity from acrylics |
WO1988000062A1 (en) * | 1986-07-04 | 1988-01-14 | Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny I | Ligature material |
US4875479A (en) * | 1986-07-04 | 1989-10-24 | Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki | Sutural material |
US4895566A (en) * | 1986-07-25 | 1990-01-23 | C. R. Bard, Inc. | Coating medical devices with cationic antibiotics |
WO1989009627A1 (en) * | 1988-04-07 | 1989-10-19 | Edward Shanbrom | Non-thrombogenic intravascular catheter coated with polymyxin |
US5009229A (en) * | 1989-12-06 | 1991-04-23 | Medtronic, Inc. | Steroid eluting intramuscular lead |
US5086787A (en) * | 1989-12-06 | 1992-02-11 | Medtronic, Inc. | Steroid eluting intramuscular lead |
EP0607284A1 (en) * | 1991-10-10 | 1994-07-27 | Menlo Care Inc. | Therapeutic agent in hydrophilic matrix |
EP0607284A4 (en) * | 1991-10-10 | 1997-06-04 | Menlo Care Inc | Therapeutic agent in hydrophilic matrix. |
US5584877A (en) * | 1993-06-25 | 1996-12-17 | Sumitomo Electric Industries, Ltd. | Antibacterial vascular prosthesis and surgical suture |
US6416549B1 (en) | 1999-07-19 | 2002-07-09 | Sulzer Carbomedics Inc. | Antithrombogenic annuloplasty ring having a biodegradable insert |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3896813A (en) | Sutures having long-lasting biocidal properties | |
DE102006001954B4 (en) | Antiseptic alginate preparation, process for their preparation, and their use | |
US3896812A (en) | Sutures having long-lasting biocidal properties | |
US4612337A (en) | Method for preparing infection-resistant materials | |
US6436422B1 (en) | Antibiotic hydrophilic polymer coating | |
US5534288A (en) | Infection-resistant surgical devices and methods of making them | |
US3642003A (en) | Sutures having long-lasting germicidal properties | |
US6866859B2 (en) | Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties | |
US5722992A (en) | Implant, its use in surgery and processes for the production thereof | |
US4581028A (en) | Infection-resistant materials and method of making same through use of sulfonamides | |
US5707736A (en) | Products having anti-microbial activity | |
DE69931159T2 (en) | ANTIMICROBIAL COMPOSITIONS CONTAINING TURROLIDINE, CITRIC ACID AND SODIUM ZITRATE | |
US20120328682A1 (en) | Particles incorporating antimicrobial agents | |
HUT74669A (en) | Central venous catheters loaded with antibiotics of the ramoplanin group preventing development of catheter related infections | |
EP0647452B1 (en) | Infection-resistant surgical devices and methods of making them | |
CN109331219A (en) | A kind of chitosan liquid dressing | |
EP0852148B1 (en) | Products having anti-microbial activity | |
CA1083961A (en) | Neomycin fatty acid salt containing surgical sutures | |
RU2749636C1 (en) | Method for obtaining antibacterial material | |
DE2232731A1 (en) | SURGICAL SUTURE MATERIAL WITH LONG-LASTING Germicidal Properties | |
Gravens et al. | The antibacterial effect of treating sutures with silver | |
JPH02307915A (en) | Antibacterial fiber product | |
Thomas et al. | Improvements in medicated tulle dressings | |
DE876446C (en) | Hemostatic sponge | |
WO2001037670A2 (en) | Antimicrobial hook and loop fastener |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PFIZER HOSPITAL PRODUCTS GROUP INC. Free format text: CHANGE OF NAME;ASSIGNOR:HOWMEDICA, INC.;REEL/FRAME:004471/0589 Effective date: 19840624 |